BioXcel Therapeutics is a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. Their lead product, IGALMI™ (dexmedetomidine) sublingual film, is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Additionally, BioXcel is investigating BXCL501, an orally dissolving film formulation of dexmedetomidine, for the acute treatment of agitation associated with Alzheimer's disease and for at-home use in bipolar and schizophrenia-related agitation. The company also has a subsidiary, OnkosXcel Therapeutics, focused on developing treatments in immuno-oncology.